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利用 Sema3F的 C末端融合蛋白（Sema3Fc）作为免疫原，免疫 4-6周龄雌
性 Balb/c小鼠，通过细胞融合技术构建可以稳定分泌靶向 Sema3F的单克隆抗体
的杂交瘤细胞株。然后扩大培养杂交瘤细胞，注射入 Balb/c小鼠腹腔中获得含有
























我们成功获得了 2株稳定分泌 Sema3Fc mAb的杂交瘤细胞株，分别命名为
G5 mAb和 E8 mAb。通过腹腔注射杂交瘤细胞得到的腹水经 rProtein A亲和柱纯
化得到了纯度较高的抗体（抗体纯度约为 90 %，浓度约为 2 mg/mL）；间接 ELISA
结果表明两株杂交瘤细胞株分泌的 Sema3Fc mAb滴度都在 1×10-5左右；硫氰酸
盐洗脱法表明 E8株抗体相对亲和力指数达到了 2.5mol/L，具有较高的亲和力。
Western blotting 结果显示 E8 mAb 与 Sema3Fc 融合蛋白及两株肝癌细胞株




组织化学染色结果表明 E8 mAb可以特异性地结合肝癌组织中的 Sema3F蛋白。
应用自制的抗体通过竞争 ELISA方法建立了定量检测 Sema3F的标准曲线，得






1本实验成功制备筛选出了 2株稳定分泌 Sema3Fc mAb的杂交瘤细胞株并
制备纯化了单克隆抗体。



















4应用 E8 mAb初步建立了定量检测 Sema3F的竞争 ELISA方法。



















That Tumor Supress Gene(TSG) suffered to be mutant or abnormal expression is
one of mechanism contributing to the initial of cancer. Many regions of human gene
could lead cells to grow out of control when they changes. As one of 19 candidate
TSGs of lung cancer, Sema3F is one member of class 3 Semaphorins ,which is also
called collapsins and firstly identified as negative mediator of axon guidance during
neuronal development. Semaphorins(Semas), also called collapsins, is firstly
identified as negative mediator of axon guidance during neuronal development. As a
member of Semas, Semaphorin3F(Sema3F) is a functional tumor suppress gene. In
the recent research, it is found that Sema3F along with its receptors are extensively
expressed in tumor cells and play crucial role in angiogenesis and tumor growth,
apoptosis, adhesion and metastasis, besides, sema3F may be invoved in regulation of
tumor magligant phenotype and possesses independent signaling pathway . clinical
studies found that the lower expression of Sema3F is tightly related to prognosis and
metastasis of liver cancer, indicating that Sema3F may be a potential prognosis mark.
Further, various experiment in vivo or in vitro demonstrated that the expression of
Sema3F similarly has effect on progression of tumor. Further understanding of
function of Sema3F in tumor biological behavior and relative signaling pathway will
be of great significance to explain the mechanism underlying in these functions and
find new target. C-terminu is importan domain, which Sema3F lies on to exert
functions, and the domain needs to be activated by furin therefore interacting with
corresponding receptors. Basing on the background above, this study aims to produce
monoclonal antibody (mAb) against Sema3F by hybridoma technique and identify the
characters of this antibody with expectation to provide basic and technique support for
clinical diagnosis, and finally apply the antibody to preliminarily explore the
















Sema3Fc was used as antigen to immune 4-6 week old Balb/c mice and establish
hybridoma stably secreting Sema3Fc mAb through the hybridoma protocol by Kohler
and Milstein. Hybridoma was intraperitoneally injected into Balb/c mice to acquire
ascites. The obtained ascites was purified by rProteinA column, freez-dried and
suffered to SDS-PAGE; indirect ELISA was used to determine the antibody titer and
thiocyanate elution method wad used to determine the relative affinity of mAb. In
addition, with mAb, regular experiments in lab such as western blotting , flow
cytometry immunofluorescence analysis, immunocytochemical staining and
immunohistochemical staining assay were used to detect Sema3F expression in liver
cancer cells line HepG2 and BEL-7402 and liver tissues, meanwhile assessing the
specificity of E8 mAb. Later, with produced Sema3Fc mAb, we developed
competitive ELISA method for quantitative detection of Sema3F, established standard
curve and analyzed sensitivity and detection limit of the method. Besides,
immunohistochemical staining assay was used to detect the expression of Sema3F in
tumor tissue chips.
Results:
We successfully established two hybridoma stably secreting Sema3Fc mAb.
Though intraperitoneally injecting hybridoma, we obtain the ascites containing
Sema3Fc mAb. After processing by rProteinA column and freeze-drying, the purity of
Sema3Fc mAb is as high as 90 % and concentration is 2mg/mL; indirect ELISA
showed that Sema3Fc mAb got the titer of 1×10-5; thiocyanate elution method
indicated the relative affinity of mAb is 2.5mol/L. In addition, Western blotting
showed the bands of 10 KDa, 90KDa and 120 KDa respectively, indicating E8 mAb
could bind to both recombinant Sema3Fc and full-length Sema3F in cancer cells;
Flow cytometry, immunofluorescence staining, immunocytochemistry and
immunohistochemica staining results indicated that Sema3F mAb could specifically
combine Sema3F expressed in liver cancer cells line and liver tissue. With produced















obtained standard curve. The regression equation of the curve is Y=0.0954x+7.1839,
the relative coefficient R2=0.9348. We designated the corresponding competitor
concentration as sensitivity when the inhibition rate reached 50%, and as detection
limit when 10%. Therefore, the sensitivity and detection limit is 448.806ng/mL and
29.52ng/mL respectively.
Conclusions:
1 We successfully establish two hybridoma cell lines stably secreting Sema3Fc
mAb and produce the abundant monoclonal antibody.
2 The titer of Sema3Fc mAb two hybridoma secreting is about 1×10-5 by indirect
ELISA method; according to isotype identification, the mAb belongs to IgM.
3 Identified by western blotting, flow cytometry, immunocytofluorescence,
immunocytochemical staining and immunohistochemical staining, the prepared E8
mAb could specifically bind to Sema3F protein expressed in liver cell lines BEL-7402
and HepG2, also in liver tissue.
4 We preliminarily developed a competitive ELISA method for quantitative
detection of Sema3F
5 With E8 mAb as detector, we analyzed the expression of Sema3F protein in
clinical pathological tissues by immunohistochemical staining, and found the
expression of Sema3F is downregulated in some tumor, indicating that Sema3F may
involved in progression of tumor.
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